Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-02-27 · accession 0002050167-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2026-02-27 | MAZE | Dandekar Atul | CSBO | S - Sale+OE | $45.43 | -7,500 | 14.3K | -34% | -$340.7K |
| D | 2026-03-03 | 2026-02-27 | MAZE | Dandekar Atul | CSBO | M - OptEx | $10.42 | +7,500 | 18.0K | +71% | +$78.2K |
| D | 2026-03-03 | 2026-02-27 | MAZE | Dandekar Atul | CSBO | M - OptEx | $0.00 | -7,500 | 59.1K | -11% | $0 |
| DM | 2026-03-03 | 2026-03-02 | MAZE | Dandekar Atul | CSBO | A - Grant | $0.00 | +57.0K | 19.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | S | D | 3,761 | $45.72 | 10,503 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.02 per share, inclusive. |
| 2 | Common | Common Stock | 2026-02-27 | M | A | 7,500 | $10.42 | 18,003 | D | — | — | |
| 3 | Common | Common Stock | 2026-02-27 | S | D | 3,739 | $45.13 | 14,264 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-02-27 | M | D | 7,500 | $0.00 | 59,143 | D | $10.42 · — to 2031-04-11 | 7,500 Common Stock | (F4) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-03-02 | A | A | 38,000 | $0.00 | 38,000 | D | $45.61 · — to 2036-03-01 | 38,000 Common Stock | (F5) The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 6 | Derivative | Restricted Stock Units | 2026-03-02 | A | A | 19,000 | $0.00 | 19,000 | D | — · — to — | 19,000 Common Stock | (F6) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. (F7) The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. (F8) These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. |